Boryana Avramova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Boryana Avramova has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Albena Spasova
Department of Pediatrics, Specialized Hospital for Active Treatment of Children’s Diseases “Prof. Ivan Mitev”, Medical University-Sofia, 1606 Sofia, Bulgaria
1 shared publication - Bogdan Mladenov
Department of Pediatric Anesthesiology and Intensive Care, University Multiprofile Hospital for Active Treatment and Emergency Medicine ‘N.I.Pirogov’, 1606 Sofia, Bulgaria
1 shared publication - Genoveva Tacheva
Children Neurology Unit, Department of Pediatric Neurology, University Pediatrics Hospital, Medical University-Sofia, 1000 Sofia, Bulgaria
1 shared publication - Hans Heinrich Kreipe
Institute of Pathology, Hannover Medical School (MHH), Hannover, Germany
1 shared publication - Hristo Shivachev
Department of Pediatric Surgery, University Multiprofile Hospital for Active Treatment and Emergency Medicine ‘N.I.Pirogov’, 1606 Sofia, Bulgaria
1 shared publication - Kaloyan Gabrovski
Department of Neurosurgery, University Hospital “St. Ivan Rilski”, Medical University–Sofia, 1431 Sofia, Bulgaria
1 shared publication
Latest Publications
- 5 March 2026
- Published by Open Source Publications in Annals of Case Reports and Medical Images
- Vol. 3 (1)
Two cases of pediatric colorectal carcinoma with atypical presentation
Pediatric colorectal carcinomas are very rare cancers, particularly before puberty,
- 5 March 2026
- Published by Open Source Publications in Annals of Case Reports and Medical Images
- Vol. 3 (1)
Two cases of pediatric colorectal carcinoma with atypical presentation
Pediatric colorectal carcinomas are very rare cancers, particularly before puberty,
- Open Access
- 23 December 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 18 (1) , 2
A Rare Case of Rhizomucor pusillus Infection in a 3-Year-Old Child with Acute Lymphoblastic Leukemia, Presenting with Lung and Brain Abscesses—Case Report
Invasive Mucormycosis (IM) is an extremely rare infection with a high mortality rate, caused by a group of fungi classified as Mucorales moulds. Rhizomucor pusillus is a saprophitic, thermophilic, and angioinvasive microorganism that grows and lives at about 45 °C and is usually found in different environmental spaces such as soil, air, water, food, and other organic matter. These features predispose the infection to wide dissemination, especially in immunocompromised patients and most often in children after chemotherapy for hematological malignancies (HMs). Mucormycosis in patients with hematologic malignancies and neutropenia represents between 0.07% and 4.29% of the concomitant diseases. IM can develop into an infection in different sites, but its most common manifestation is pulmonary, followed by rhino-orbital–cerebral and disseminated forms. In recent years, an increased morbidity rate has been associated with the ongoing COVID-19 pandemic, as cited in the literature. There are many publications with COVID-19-associated mucormycosis (CAM) cases. The present treatment protocol includes extensive and radical surgical debridement and systemic antifungal therapy with Liposomal Amphotericin B (L-AmB), Posaconazole, and Isavuconazole, either combined or as monotherapy. Despite these new treatment modalities, the mortality rate remains over 50%. We present a rare case of a 3-year-old child with acute lymphoblastic leukemia (ALL) and systemic Rhizomucor pusillus infection, diagnosed on the occasion of lung and brain abscesses. The patient underwent lung and brain surgery and is recovering well with no further complications. The two-year follow-up period shows no signs of recurrence of the disease.
- 23 December 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 18 (1) , 2
Open AccessA Rare Case of Rhizomucor pusillus Infection in a 3-Year-Old Child with Acute Lymphoblastic Leukemia, Presenting with Lung and Brain Abscesses—Case Report
Invasive Mucormycosis (IM) is an extremely rare infection with a high mortality rate, caused by a group of fungi classified as Mucorales moulds. Rhizomucor pusillus is a saprophitic, thermophilic, and angioinvasive microorganism that grows and lives at about 45 °C and is usually found in different environmental spaces such as soil, air, water, food, and other organic matter. These features predispose the infection to wide dissemination, especially in immunocompromised patients and most often in children after chemotherapy for hematological malignancies (HMs). Mucormycosis in patients with hematologic malignancies and neutropenia represents between 0.07% and 4.29% of the concomitant diseases. IM can develop into an infection in different sites, but its most common manifestation is pulmonary, followed by rhino-orbital–cerebral and disseminated forms. In recent years, an increased morbidity rate has been associated with the ongoing COVID-19 pandemic, as cited in the literature. There are many publications with COVID-19-associated mucormycosis (CAM) cases. The present treatment protocol includes extensive and radical surgical debridement and systemic antifungal therapy with Liposomal Amphotericin B (L-AmB), Posaconazole, and Isavuconazole, either combined or as monotherapy. Despite these new treatment modalities, the mortality rate remains over 50%. We present a rare case of a 3-year-old child with acute lymphoblastic leukemia (ALL) and systemic Rhizomucor pusillus infection, diagnosed on the occasion of lung and brain abscesses. The patient underwent lung and brain surgery and is recovering well with no further complications. The two-year follow-up period shows no signs of recurrence of the disease.